The myth of reserpine-induced depression: Role in the historical development of the monoamine hypothesis

Journal of the History of the Neurosciences

Volumn 12, Issue 2, 2003, Pages 207-220

  Baumeister, Alan A ^a   Hawkins, Mike F ^a   Uzelac, Sarah M ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Biological psychiatry; Depression; History; Monoamine hypothesis; Reserpine

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BRAIN MONOAMINE; CHLORPROMAZINE; HEXOBARBITAL; IMIPRAMINE; IPRONIAZID; ISONIAZID; LYSERGIDE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NICOTINAMIDE; RAUWOLFIA ALKALOID; RESERPINE; SEROTONIN; TRANYLCYPROMINE;

ANTIHYPERTENSIVE ACTIVITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; ELECTROCONVULSIVE THERAPY; EUPHORIA; HISTORY OF MEDICINE; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPOTHESIS; INDIA; JAUNDICE; MENTAL DISEASE; MONOAMINE METABOLISM; MOOD; MOOD DISORDER; NONHUMAN; PSYCHIATRY; RAUWOLFIA; REFLEX; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINUS TACHYCARDIA; SNAKEBITE; SYMPTOM; TUBERCULOSIS; WELLBEING; WITHDRAWAL SYNDROME; XEROSTOMIA;

BIOGENIC MONOAMINES; DEPRESSION; HISTORY, 20TH CENTURY; HUMANS; RESERPINE;

EID: 0043132076     PISSN: 0964704X     EISSN: None     Source Type: Journal    
DOI: 10.1076/jhin.12.2.207.15535     Document Type: Review

References (102)

1. Achor RWP, Hanson NO, Gifford RW (1955): Hypertension treated with Rauwolfia Serpintina (whole root) and with reserpine. Am Med Ass J 159: 841-845.
2. Ambrosino SV (1974): Depressive reactions associated with reserpine. NY State J Med 74: 860-864.
3. American Psychiatric Association (1994): Diagnostic and Statistical Manual of Mental Disorders (4th ed.), Washington, DC, American Psychiatric Association.
4. Amsterdam JD, Berwish N (1987): Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy. J Clin Psychopharm 7: 238-242.
5. Andreasen NC, Black DW (1995): Introductory Textbook of Psychiatry, Washington, DC, American Psychiatric Press.
6. Ashcroft GW, Sharman DF (1960): 5-hydroxyindoles in human cerebrospinal fluids. Nature 186: 1050-1051.
7. Avorn J, Everitt DE, Weiss S (1986): Increased antidepressant use in patients prescribed β-blockers. Am Med Ass J 255: 357-360.
8. 3-Norepinephrine by tissues. Science 133: 383-384.
9. Ayd FJ (1958): Drug-induced depression - fact or fallacy. NY State J Med 58: 354-356.
10. Bant WP (1978): Antihypertensive drugs and depression: A reappraisal. Psychol Med 8: 275-283.
11. Barsa JA, Kline NS (1955): Treatment of two hundred disturbed psychotics with reserpine. Am Med Ass J 158: 110-113.
12. Baumeister AA (2000): The Tulane electrical brain stimulation program: A historical case study in medical ethics. J Hist Neurosci 9: 262-278.
13. Baumeister AA, Francis JL (in press): Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci.
14. Bernstein S, Kaufman MR (1960): A psychological analysis of apparent depression following Rauwolfia therapy. J Mount Sinai Hospital 27: 525-530.
15. Bertler Å, Carlsson A, Rosengren E (1956): Release by reserpine of catechol amines from rabbits' hearts. Naturwissenschaften 43: 521.
16. Bhatia BB (1942): On the use of Rauwolfia serpentina in high blood pressure. J Indian Med Ass 11: 262-265.
17. Brodie BB, Shore PA, Silver SL, Pulver R (1955): Potentiating action of chlorpromazine and reserpine. Nature 175: 1133-1134.
18. Bunney WE, Davis JM (1965): Norepinephrine in depressive reactions. Arch Gen Psychiat 13: 483-494.
19. Burrell RH (1955): Reserpine depression treated with sodium succinate. New Zealand Med J 54: 565-567.
20. Carlsson A, Lindqvist M, Magnusson (1957): 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180: 1200.
21. Chessin M, Dubnick B, Kramer ER, Scott CC (1956): Modifications of pharmacology of reserpine and serotonin by iproniazid. Fed Proc 15: 409.
22. Coppen A (1967): The biochemistry of affective disorders. Brit J Psychiat 113: 1237-1264.
23. Coppen A, Shaw DM, Farrell JP (1963): Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 2: 79-81.
24. Crane GE (1956a): The psychiatric side-effects of iproniazid. Am J Psychiat 112: 494-501.
25. Crane GE (1956b): Further studies on iproniazid phosphate. J Nerv Ment Dis 124: 322-331.
26. Crane GE (1957): Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases. Psychiat Res Rep 8: 142-152.
27. Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W (1985): Long-term surveillance for adverse effects of antihypertensive drugs. Am Med Ass J 253: 3263-3268.
28. Davies DL, Shepherd M (1955): Reserpine in the treatment of anxious and depressed patients. Lancet 2: 117-120.
29. Delay J, Lainé B, Buisson JF (1952): Note concernant l'action de l'isonicotinyl-hydrazide utilisé dans le traitement des états dépressifs. Ann Méd Psych 2: 689-692.
30. Doyle AE, McQueen EG, Smirk FH (1955): Treatment of hypertension with reserpine, with reserpine in combination with pentapyrrolidinium, and with reserpine in combination with veratrum alkaloids. Circ Res 11: 170-181.
31. Doyle AE, Smirk FH (1954): Hypotensive action of reserpin. Lancet 1: 1096-1097.
32. Dustan HP, Taylor RD, Corcoran AC, Page IH (1954): Clinical experience with reserpine (Serpasil): A controlled study. Ann NY Acad Sci 59: 136-140.
33. Everett GM, Toman JEP (1959): Mode of action of Rauwolfia alkaloids and motor activity. In: Masserman JH, ed., Biological Psychiatry. Proceedings of the Society of Biological Psychiatry San Francisco, May 1958. New York: Grune & Stratton, pp. 75-81.
34. Faucett RL, Litin EM, Achor RWP (1957): Neuropharmacologic action of Rauwolfia compounds and its psychodynamic implications. Arch Neurol Psychiat 77: 513-518.
35. Feldman RS, Meyer JS, Quenzer LF (1997): Principles of Neuropsychopharmacology. Sunderland, MA: Sinauer Associates, Inc.
36. Floody RJ, Dixon RE, Mattia VD (1958): Marsilid toxicity. Dis Nerv Sys 19: 541-544.
37. Fox HH (1952): The chemical approach to the control of tuberculosis. Science 116: 129-134.
38. Freis ED (1954): Mental depression in hypertensive patients treated for long periods with large doses of reserpine. New Engl. J Med 251: 1006-1008.
39. Genest J, Adamkiewicz L, Robillard R, Tremblay G (1955): Clinical uses of Rauwolfia. Can Med Assoc J 72: 483-489.
40. Harris TH (1957): Depression induced by Rauwolfia compounds. Am J Psychiat 113: 950.
41. Healy D (1997): The Antidepressant Era. Cambridge: Harvard University Press.
42. Healy D (2000): The case for an individual approach to the treatment of depression. J Clin Psychiat 61: 18-23.
43. Healy D (2002): The Creation of Psychopharmacology. Cambridge: Harvard University Press.
44. Healy D, Savage M (1998): Reserpine exhumed. Brit J Psychiat 172: 376-378.
45. Henry JP, Scherman D (1989): Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem Pharmacol 38: 2395-2404.
46. Hess SM, Shore PA, Brodie BB (1956): Persistence of reserpine action after the disappearance of drug from brain: Effect on serotonin. J Pharmacol Exp Ther 118: 84-89.
47. Hopkinson G, Kenny F (1975): Treatment with reserpine of patients resistant to tricyclic antidepressants. Psychiatria Clin 8: 109-114.
48. Jacobsen E (1964): The theoretical basis of the chemotherapy of depression. In Davies EB, ed., Depression. Proceedings of the Symposium Held at Cambridge 22 to 26 September 1959. London: Cambridge University Press, pp. 208-213.
49. Janicak PG, Davis JM, Preskorn SH, Ayd FJ (1993): Principles and Practice of Psychopharmacotherapy. Baltimore: Williams & Wilkins.
50. Jensen K (1959): Depressions in patients treated with reserpine for arterial hypertension. Acta Psychiat Scand 34: 195-204.
51. Kamman GR, Freeman JG, Lucero RJ (1953): The effect of 1-isonicotynl 2-isopropyl hydrazide (IIH) on the behavior of long-term mental patients. J Nerv Ment Dis 118: 391-407.
52. Kass I, Brown EC (1955): Treatment of hypertensive Patients with Rauwolfia compounds and reserpine. Am Med Ass J 159: 1513-1516.
53. Kirk L, Gram LF, Jensen PS (1970): Clinical experience with 10 mg reserpin injected i.m. in depressive disorders. Acta Psychiatr Scand 217: 55-56.
54. Kline NS (1954): Use of Rauwolfia serpentina Benth. in neuropsychiatric conditions. An NY Acad Sci 59: 107-132.
55. Kline NS (1958): Clinical experience with iproniazid (Marsilid). J Clin Exp Psychopathol 19 (Suppl 1): 72-78.
56. Kline NS (1964): The practical management of depression. Am Med Assn J 190: 122-130.
57. Kline NS (1965): Lasker award: Priority claim. Am Med Assn J 191: 161-162.
58. Kline NS (1970): Monoamine oxidase inhibitors: An unfinished picaresque tale. In: Ayd FJ, Blackwell B, eds., Discoveries in Biological Psychiatry. Philadelphia: J.B. Lippincott Company, 194-204.
59. Lehmann HE, Kline NS (1983): Clinical discoveries with antidepressant drugs. In: Parnham MJ, Bruinvels J, eds., Discoveries in Pharmacology, Volume 1: Psycho- and Neuropharmacology. New York: Elsevier, pp. 209-221.
60. Lemieux G, Davignon A, Genest J (1956): Depressive states during Rauwolfia therapy for arterial hypertension. Canad Med Ass J 74: 522-526.
61. Locket S (1955): Oral preparations of Rauwolfia serpentina in treatment of essential hypertension. Br Med J 1: 809-813.
62. Loomer HP, Saunders JC, Kline NS (1957): A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiat Res Rep 8: 129-141.
63. Macarthur JG, Isaacs B (1955): Mental effects of reserpine. Lancet 2: 347.
64. Maggs R, Ellison RM (1960): Five-year follow-up of results of reserpine therapy in mental hospital practice. J Ment Sci 106: 590-598.
65. Margolis LH (1957): Pharmacotherapy in psychiatry: A review. An NY Acad Sci 66: 698-717.
66. Marshall EF, Stirling GS, Tait AC, Todrick A (1960): The effect of iproniazid and imipramine on the blood platelet 5-hydroxytryptamine level in man. Brit J Pharmacol 15: 35-41.
67. Muller JC, Pryor WW, Gibbons JE, Orgain ES (1955): Depression and anxiety occurring during Rauwolfia therapy. Am Med Ass J 159: 836-839.
68. Müller JM, Schlittler E, Bein HJ (1952): Reserpin, der sedative Wirkstoff aus Rauwolfia serpentina Benth. Experientia 8: 338.
69. Musselman DL, DeBattista C, Nathan KI, Kilts CD, Schatzberg AF, Nemeroff CB (1998): Biology of mood disorders. In: Schatzberg AF, Nemeroff CB, eds., Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press, pp. 549-588.
70. Nemeroff CB (1998): The neurobiology of depression. Scientific American 278 (June): 42-49.
71. Nemeroff CB (2002): Comorbidity of mood and anxiety disorders: The rule, not the exception? Am J Psychiat 159: 3-4.
72. Neylan TC (1995): Pathophysiology of affective disorders: Joseph J. Schildkraut's Catecholamine Hypothesis. J Neuropsychiat 7: 523-524.
73. Oates JA, Sjoerdsma A (1960): Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 10: 1076-1078.
74. Pollin W, Cardon PV, Kety SS (1961): Effects of amino acid feedings in schizophrenic patients treated with iproniazid. Science 133: 104-105.
75. Price LH, Charney DS, Heninger GR (1987): Reserpine augmentation of desipramine in refractory depression: Clinical and neurobiological effects. Psychopharmacology 92: 431-437.
76. Prisant LM, Spruill WJ, Fincham JE, Wade WE, Carr AA, Adams MA (1991): Depression associated with antihypertensive drugs. J Fam Pract 33: 481-485.
77. Quetsch RM, Achor RWP, Litin EM, Faucett RL (1959): Depressive reactions in hypertensive patients. A comparison of those treated with Rauwolfia and those receiving no specific antihypertensive treatment. Circulation 19: 366-375.
78. Robitzek EH, Selikoff IJ, Ornstein GG (1952): Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid. Quart Bull Sea View Hospital 13: 27-51.
79. Salzer HM, Lurie ML (1953): Anxiety and depressive states treated with isonicotinyl hydrazid (isoniazid). Arch Neurol Psychiat 70: 317-324.
80. Schildkraut JJ (1965): The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiat 122: 509-522.
81. Schroeder HA, Perry HM (1955): Psychosis apparently produced by reserpine. Am Med Ass J 159: 839-840.
82. Selikoff IJ, Robitzek EH, Ornstein GG (1952): Toxicity of hydrazine derivatives of isonicotinic acid in the chemotherapy of human tuberculosis. Quart Bull Sea View Hospital 13: 17-26.
83. Shore PA, Silver SL, Brodie BB (1955a): Interaction of serotonin and lysergic acid diethylamide (LSD) in the central nervous system. Experientia 11: 272-273.
84. Shore PA, Silver SL, Brodie BB (1955b): Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science 122: 284-285.
85. Siddiqui S, Siddiqui RH (1931): Chemical examination of the roots of Rauwolfia serpentina, benth. J Indian Chem Soc 8: 667-678.
86. Smith B, Prockop DJ (1962): Central-nervous-system effects of ingestion of L-tryptophan by normal subjects. New Eng J Med 267: 1338-1341.
87. Smith JA (1953): The use of the isopropyl derivative of isonicotinylhydrazine (Marsilid) in the treatment of mental disease. Am Pract 4: 519-520.
88. Swazey JP (1974): Chlorpromazine in Psychiatry. A Study of Therapeutic Innovation. Cambridge, MA, The MIT Press.
89. Thaler L, Wassertheil-Smoller S, Blaufox MD, Oberman A, Langford HG (1993): Effect of withdrawal of antihypertensive drug on depressive mood. Am J Hypertens 6: 1055-1062.
90. Tourney G, Isberg EM, Gottlieb JS (1955): The use of reserpine in an acute psychiatric treatment setting. Am Med Ass Arch Neurol Psychiat 74: 325-328.
91. Twarog BM, Page IH (1953): Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 175: 157-161.
92. Vakil RJ (1949): A clinical trial of Rauwolfia serpentina in essential hypertension. Br Heart J 11: 350-355.
93. Valenstein ES (1998): Blaming the Brain. New York, The Free Press.
94. Veterans Administration (1967): Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. Am Med Ass J 202: 1028-1034.
95. Veterans Administration (1970): Effects of treatment on morbidity in hypertension II: Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. Am Med Ass J 213: 1143-1152.
96. Wallace DC (1955): Treatment of hypertension. Hypotensive drugs and mental changes. Lancet 2: 116-117.
97. Wilkins RW (1952): New drug therapies in arterial hypertension. Annals Int Med 37: 1144-1155.
98. Wilkins RW, Judson WE (1953): Problems arising from the use of hypotensive drugs in hypertensive patients. Trans Ass Am Physicians 66: 175-189.
99. Wilkins RW, Judson WE, Stone RW, Hollander W, Huckabee WE, Friedman IH (1954): Reserpine in the treatment of hypertension. New England J Med 250: 477-478.
100. Winokur G, Clayton PJ, Reich T (1969): Manic Depressive Illness. Saint Louis: C.V. Mosby Company.
101. Winokur G, Tsuang MT (1996): The Natural History of Mania, Depression, and Schizophrenia, Washington, DC, American Psychiatric Press.
102. Zeller EA, Barsky J, Fouts JR, Kirch-Heimer WF, Orden van LS (1952): Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia 8: 349-350.